+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

CYP2D6 polymorphism in a Gabonese population: Contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype



CYP2D6 polymorphism in a Gabonese population: Contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype



British Journal of Clinical Pharmacology 47(1): 121-124



Aims. To determine the molecular basis of the intermediate extensive metaboliser (EM) CYP2D6 phenotype in healthy Gabonese subjects. Methods. The CYP2D6 phenotype of 154 healthy Gabonese subjects was assessed by giving the subject a single dose of 30 mg dextromethorphan, and collecting their urine for the next 8 h. The CYP2D6 genotype was determined for 50 individuals of the EM phenotypic group by Southern blotting and various PCK-based procedures aimed at identifying different CYP2D6 alleles. Results. We found that in the studied Gabonese population, as compared with a French population, there is significantly higher frequency of intermediate EM phenotype having lower frequency of CYP2D6 PM alleles. To clarify this discrepancy phenotype-genotype relationship was studied. We found that the CYP2D6*17 and CYP2D6*2 alleles, prevalent in this black population, are characterised by their low capacity for dextromethorphan demethylation. Our data also show that the CYP2D6*1 allele is associated with the highest in vivo activity followed by the CYP2D6*2 allele and then the CYP2D6*17 allele. Conclusions. The higher frequencies of the CYP2D6*2 and CYP2D6*17 alleles than the CYP2D6*1 allele account for the high frequency of the intermediate EM phenotype in this black population. The polymorphism of the CYP2D6 enzyme activity in Affican populations could have important implications for use of drugs that are substrates for CYP2D6 and have a narrow therapeutic window.

(PDF emailed within 0-6 h: $19.90)

Accession: 010265868

Download citation: RISBibTeXText

PMID: 10073750

DOI: 10.1046/j.1365-2125.1999.00861.x


Related references

Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clinical Chemistry 46(8 Pt 1): 1072-1077, 2000

Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. British Journal of Clinical Pharmacology 2018, 2018

Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population. Clinical Pharmacology and Therapeutics 81(1): 95-98, 2007

CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics 10(6): 567-570, 2000

Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. British Journal of Clinical Pharmacology 50(1): 31-34, 2000

Influence of donor and recipient genotypes on CYP2D6 phenotype after liver transplantation: A study of mutations CYP2D6*3 and CYP2D6*4. European Journal of Clinical Pharmacology 54(1): 47-52, 1998

Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metabolism and Disposition 30(5): 595-601, 2002

Novel single nucleotide polymorphisms in the CYP2D6 gene associated with CYP2D6*2 and/or CYP2D6*10 alleles. Drug Metabolism and Pharmacokinetics 17(5): 475-478, 2004

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment. Breast Cancer 8: 149-155, 2016

Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: Therapeutic consequences?. European Journal of Clinical Pharmacology 55(11-12): 877-879, 2000

Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. European Journal of Clinical Pharmacology 51(2): 117-122, 1996

Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics 4(3): 154-158, 1994

Sequence-based analysis of the CYP2D6*36-CYP2D6*10 tandem-type arrangement, a major CYP2D6*10 haplotype in the Japanese population. Drug Metabolism and Pharmacokinetics 21(3): 208-216, 2006

Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metabolism and Disposition: the Biological Fate of Chemicals 35(8): 1292-1300, 2007

Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3, *4, and *6) within an Iranian population (Mazandaran). Genetic Testing and Molecular Biomarkers 15(11): 821-825, 2012